Medical News

RSS

COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate

Results from a pre-specified interim analysis of a randomized, placebo-controlled Phase 3 study, COU-AA-301, demonstrate that patients treated with the investigational agent abiraterone acetate plus low-dose prednisone/prednisolone showed a significant improvement in overall survival compared to patients treated with prednisone/prednisolone plus placebo.

11 Oct 2010

Varian and Stanford scientists receive $3.6M NIH grant to develop advanced imaging technology

Scientists from Stanford University and from the Ginzton Technology Center at Varian Medical Systems have jointly received a $3.6 million five-year research grant from the U.S. National Institutes of Health (NIH) to develop advanced imaging technology for improving the quality of CT images for patients with metal objects in their bodies such as hip implants and dental fillings.

11 Oct 2010

Sales of Merck's telcagepant and CoLucid's lasmiditan in world's major markets to reach $1.3 billion in 2019

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that two first-in-class agents — Merck's telcagepant and CoLucid's lasmiditan — will earn combined sales of approximately $1.3 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

11 Oct 2010

Gelesis presents lead products data at Obesity 2010 Annual Meeting

Gelesis, Inc., a Boston-based company focused on breakthrough treatments for obesity, presented new results at Obesity 2010, the 28th Annual Scientific Meeting of The Obesity Society (San Diego). The new data demonstrated that its lead products (Attiva and Gellica) dramatically reduced food intake in a gold-standard animal model compared to administration of an equal amount of water.

11 Oct 2010

Agilex named region's fastest growing company by Washington Business Journal

Agilex Technologies, Inc., a leading provider of mission and technology solutions to the national security, healthcare and public sectors, announced today it was named the region's fastest growing company by the Washington Business Journal. In the company's first year of eligibility, Agilex debuted at the top of the list with reported three year growth of 372.32% and total revenue of $38M (FY2009). This annual ranking covers the entire Washington, DC metro area.

11 Oct 2010

Arable introduces CTMS and EDC software for clinical organizations

Arable Corporation has announced the launch of Arable Perform to bring unique CTMS technologies to the clinical trial industry. Whereas traditional CTMS systems have been costly and require months to implement, Perform brings CTMS and EDC capabilities without the traditionally high start-up costs.

11 Oct 2010

IRIDEX introduces new family of Adjustable & Intuitive EndoProbe laser handpieces

IRIDEX Corporation today announced commercial availability of a new family of Adjustable & Intuitive EndoProbe laser handpieces for use with the Company's laser platforms in vitreoretinal surgery.

11 Oct 2010

TruTouch secures grant to accelerate development of next-generation technology platform

TruTouch Technologies, a pioneer in non-invasive biometric intoxication detection systems, today announced that it has secured a $438,000 grant to accelerate the development of its next-generation technology platform.

11 Oct 2010

ArQule announces SPA with FDA for ARQ 197 Phase 3 trial design for NSCLC

ArQule, Inc. today announced a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the design of a Phase 3 trial of ARQ 197 in patients with non-small cell lung cancer (NSCLC) of non-squamous histology.

11 Oct 2010

MingSight acquires worldwide rights from Pfizer to develop new chemical entities for human diseases

MingSight Pharmaceuticals announced today that it has acquired the exclusive worldwide rights from Pfizer to develop, manufacture, and commercialize two preclinical stage new chemical entities for the prevention and treatment of human diseases.

11 Oct 2010

Prescription Solutions' MS DTM program wins URAC Best Practices Platinum Award

Prescription Solutions, a leading pharmacy benefits management (PBM) organization and a UnitedHealth Group company, received a platinum award in the URAC Best Practices in Health Care Consumer Empowerment and Protection Awards. Prescription Solutions was recognized for its Multiple Sclerosis Disease Therapy Management (MS DTM) program, which empowers patients through education and support to successfully attain skills in self-managing their symptoms and medication therapy for their chronic condition.

11 Oct 2010

Genta announces EMA Orphan Drug designation for tesetaxel

Genta Incorporated today announced that tesetaxel, the leading oral taxane in clinical development, has been designated as an Orphan Drug by the European Medicines Agency for gastric cancer. The drug has previously received Orphan Drug designation by the U.S. Food and Drug Administration for both gastric cancer and melanoma, as well as Fast Track designation by FDA for gastric cancer.

11 Oct 2010

Innate Therapeutics initiates MIS416 Phase 2a clinical study in patients with progressive multiple sclerosis

Innate Therapeutics today announced that the company has begun treating patients in a Phase 2a clinical study of its lead molecule, MIS416, in patients with progressive multiple sclerosis (MS).

11 Oct 2010

Genentech initiates GDC-0449 Phase II clinical trial in BCC patients

Curis, Inc. a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC).

11 Oct 2010

FDA approves Warner Chilcott's ACTONEL for postmenopausal osteoporosis

Warner Chilcott plc today announced that the United States Food and Drug Administration (FDA) has approved its next generation ACTONEL® (risedronate sodium) product for the treatment of postmenopausal osteoporosis in the United States. The product will be marketed as ATELVIA™ (risedronate sodium) delayed-release tablets.

11 Oct 2010

Micromet to initiate MEDI-565 Phase 1 trial in patients with advanced gastrointestinal cancer

Micromet, Inc. today announced that its licensee for MT111, MedImmune, plans to initiate a Phase 1 trial in patients with advanced gastrointestinal cancers based on an investigational new drug (IND) application recently accepted by the U.S. Food and Drug Administration (FDA).

11 Oct 2010

The insurance straw man

In this Kaiser Health News column, James C. Capretta of the Ethics and Public Policy Center criticizes Health and Human Services Secretary Kathleen Sebelius for some of her tough tactics with insurance companies.

11 Oct 2010

Class action lawsuit against DePuy Orthopaedics

The preeminent law office of Nurenberg, Paris, Heller & McCarthy has filed a class action lawsuit against Johnson & Johnson's artificial joint replacement company DePuy Orthopaedics, Inc., on behalf of clients who suffered damages resulting from the company's now-recalled hip replacement device. (Case No. 1:10CV02222, U.S. District Court, Northern District of Ohio, Eastern Division)

11 Oct 2010

AVEO presents tivozanib Phase 2 study results at ESMO Congress

AVEO Pharmaceuticals, Inc. a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) were presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.

11 Oct 2010

Icagen regains compliance with Nasdaq Global Market price requirement

Icagen, Inc. today announced that it has regained compliance with the Nasdaq Global Market's $1.00 minimum bid price requirement.

11 Oct 2010

Medical News

COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate

Varian and Stanford scientists receive $3.6M NIH grant to develop advanced imaging technology

Sales of Merck's telcagepant and CoLucid's lasmiditan in world's major markets to reach $1.3 billion in 2019

Gelesis presents lead products data at Obesity 2010 Annual Meeting

Agilex named region's fastest growing company by Washington Business Journal

Arable introduces CTMS and EDC software for clinical organizations

IRIDEX introduces new family of Adjustable & Intuitive EndoProbe laser handpieces

TruTouch secures grant to accelerate development of next-generation technology platform

ArQule announces SPA with FDA for ARQ 197 Phase 3 trial design for NSCLC

MingSight acquires worldwide rights from Pfizer to develop new chemical entities for human diseases

Prescription Solutions' MS DTM program wins URAC Best Practices Platinum Award

Genta announces EMA Orphan Drug designation for tesetaxel

Innate Therapeutics initiates MIS416 Phase 2a clinical study in patients with progressive multiple sclerosis

Genentech initiates GDC-0449 Phase II clinical trial in BCC patients

FDA approves Warner Chilcott's ACTONEL for postmenopausal osteoporosis

Micromet to initiate MEDI-565 Phase 1 trial in patients with advanced gastrointestinal cancer

The insurance straw man

Class action lawsuit against DePuy Orthopaedics

AVEO presents tivozanib Phase 2 study results at ESMO Congress

Icagen regains compliance with Nasdaq Global Market price requirement

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

The importance of ketones from a clinical and medical perspective

Latest News